Im YH - Search Results

1

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Masuda N, et al. Among authors: im yh, im sa. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. N Engl J Med. 2017. PMID: 28564564 Free article. Clinical Trial.

2

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.

Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Lim DH, et al. Among authors: im yh. Cancer Chemother Pharmacol. 2005 Jul;56(1):10-4. doi: 10.1007/s00280-004-0963-2. Epub 2005 Mar 22. Cancer Chemother Pharmacol. 2005. PMID: 15782313 Clinical Trial.

3

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: im yh. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.

4

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. Kim S, et al. Among authors: im yh. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85. doi: 10.1016/j.ijrobp.2005.05.005. Epub 2005 Aug 15. Int J Radiat Oncol Biol Phys. 2005. PMID: 16099596

5

Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K, Shim YM. Lee J, et al. Among authors: im yh. Ann Thorac Surg. 2005 Oct;80(4):1170-5. doi: 10.1016/j.athoracsur.2005.03.058. Ann Thorac Surg. 2005. PMID: 16181835 Clinical Trial.

6

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.

Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. Lee J, et al. Among authors: im yh. Cancer Chemother Pharmacol. 2008 Jun;62(1):77-84. doi: 10.1007/s00280-007-0577-6. Epub 2007 Aug 31. Cancer Chemother Pharmacol. 2008. PMID: 17762932 Clinical Trial.

7

Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.

Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH. Kim HJ, et al. Among authors: im yh. Acta Oncol. 2007;46(7):996-1003. doi: 10.1080/02841860701373587. Acta Oncol. 2007. PMID: 17851879

8

Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).

Lee SG, Jee YG, Chung HC, Kim SB, Ro J, Im YH, Im SA, Seo JH. Lee SG, et al. Among authors: im yh, im sa. Breast Cancer Res Treat. 2009 Apr;114(3):589-95. doi: 10.1007/s10549-008-0035-0. Epub 2008 Apr 25. Breast Cancer Res Treat. 2009. PMID: 18437555

9

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Uhm JE, et al. Among authors: im yh. Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090. Int J Cancer. 2009. PMID: 19065658 Free article.

10

Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer.

Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH. Kim HS, et al. Among authors: im yh. Breast Cancer Res Treat. 2009 Nov;118(1):89-97. doi: 10.1007/s10549-009-0377-2. Epub 2009 Mar 26. Breast Cancer Res Treat. 2009. PMID: 19322651

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page